Free shipping on all U.S. orders over $250 · Local pickup available in Morgan Hill, CA
PureLab Performancepurelabperformance.com
FDA-approved drugMetabolic ResearchNN2211

Liraglutide

A synthetic analog of the gut hormone GLP-1, developed by Novo Nordisk and FDA-approved as a prescription drug. It has a large body of human clinical-trial data and many rodent studies.

Evidence: strong · Peer-reviewed phase 3 human data

At a glance

Class
GLP-1 receptor agonist
Developer
Novo Nordisk
FDA status
FDA-approved prescription drug (brands: Victoza, Saxenda). This page covers the research compound only.
Human data
Multiple randomized phase 3 trials, including a pediatric trial published in NEJM in 2025
Animal / lab data
Brain-circuit, bone and metabolic studies in mice and rats, 2024–2025

Where it’s been studied

123
  • 1Brain (lateral septum)Feeding-behavior studies, mice (2024)
  • 2BoneHigh-fat diet plus STZ model, rats (2024); review of 17 rodent studies (2024)
  • 3NeutrophilsNeutrophil extracellular trap markers in bone tissue, rats (2024)

Mechanism studied

Liraglutide activates the GLP-1 receptor, the same receptor targeted by the body's own GLP-1 hormone [1]. In mice, researchers identified GLP-1 receptor-positive neurons in the lateral septum of the brain and reported that these neurons were needed for liraglutide's measured effects on feeding-related endpoints [2]. In rat bone studies, researchers proposed a pathway involving SIRT1 and neutrophil extracellular traps; this remains a proposed mechanism from small animal studies [3][4].

What the research shows

StudyModelReported resultSource
SCALE Kids, phase 3a [1]Human
82 children aged 6 to under 12, randomized 2:1, placebo-controlled, 56 weeks plus 26-week follow-up
Primary endpoint: a prespecified body-composition measure (see publication). PublishedPeer-reviewed
NEJM 2025
Lateral septum neuron study [2]Mouse
Mice with GLP-1 receptor-positive neurons in the lateral septum monitored or silenced
Researchers reported these neurons mediated liraglutide's measured reductions in food intake and body weightPeer-reviewed
J Clin Invest 2024
Bone and neutrophil trap study [3]Rat
High-fat diet plus streptozotocin model, n=5 per group, 12 weeks; rat bone marrow stromal cells
Femur NET markers lower (MPO down 56-65%, cit-H3 down 37-54%); SIRT1 up 71-91%; bone formation markers higher vs untreated modelPeer-reviewed
Iran J Pharm Res 2024
Systematic review of bone studies [4]Review
17 rodent studies, mostly ovariectomy and/or streptozotocin-induction models in rats
Pooled femur bone mineral density higher vs controls (SMD 1.95, 10 studies); authors rate study quality as modestPeer-reviewed
Front Endocrinol 2024

Human trials are listed for research context only; outcomes are reported in the linked publications. Animal and lab results do not establish effects in humans.

Supply

PureLab does not supply this compound. This page summarizes published research only.

More in Metabolic Research

Sources

  1. Fox CK et al. (2025). doi:10.1056/NEJMoa2407379 Source
  2. Chen Z et al. (2024). doi:10.1172/JCI178239 Source
  3. Zhong S et al. (2024). doi:10.5812/ijpr-148139 Source
  4. Wu Z et al. (2024). doi:10.3389/fendo.2024.1378291 Source
For research use only. Not for human or veterinary use. Not a drug, food or cosmetic, and not intended to diagnose, treat, cure or prevent any disease. This library summarizes published research for educational purposes. PureLab Performance Inc.